Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis (NCT07694466) | Clinical Trial Compass
Not Yet RecruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
United States12 participantsStarted 2026-09-01
Plain-language summary
This outpatient study examines how inhaled cannabis, combustible or vaporized, alters lung health and breath biomarkers compared to a tobacco cigarette.
Who can participate
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. English-speaking,
. Literate adults,
. Male or female,
. Between the ages of 18 and 55,
. Body Mass Index from 18.5 and 32.0 kg/m2,
. Able to provide written informed consent and perform all study procedures,
. Current recreational cannabis users - must report past 30-day cannabis use and at least 5 exposures in the past year (minimum use criteria); no limit on maximum use,
. Past year history of vaporized or smoked cannabis use to intoxication,
Exclusion criteria
. Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
. Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \[e.g., asthma, COPD\]),
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Exhaled Breath Condensate (EBC)
Timeframe: Baseline (prior to study drug admission), approximately 25, 40,60, 90, 120 and 180 minutes after drug administration
2
Breath Volatile Organic Compound (BVOC)
Timeframe: Baseline (prior to study drug admission), approximately 25, 40,60, 90, 120 and 180 minutes after drug administration
3
Exhaled Nitric Oxide (FeNO)
Timeframe: Baseline (prior to study drug admission), approximately 25, 40,60, 90, 120 and 180 minutes after drug administration
. Existing or significant lung health problems that could interfere with the study,
. Current or history of major psychiatric disorder that would limit the participant's ability to participate in the study (e.g., bipolar disorder),
. Exclusive use of tobacco or cannabis through vapes and Electronic Nicotine Delivery Systems (ENDS) products,
. Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study (as determined by the study physician),
. Clinically significant abnormal ECG (as determined by study physician/cardiologist),
. Clinically significant abnormal laboratory findings (e.g., liver function tests greater than 3x the upper limits of normal range),